Project Grant FF204K114021

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...

This $275,000 SBIR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop antibody therapeutics for the treatment of stage 3 type-1 diabetes (T1D). The project by Islex Therapeutics, LLC seeks to harness the synergistic effects of autoimmune protection, insulin supplementation, and targeted delivery of mitogenic drugs to the pancreatic islet, the specific disease site of T1D. The research...

This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,207,770.00 to The Trustees of Columbia University in the City of New York for a project titled "Understanding Thymic Epithelial and Hematopoietic Stem Cell-Intrinsic Immune Abnormalities Driving T1D in Optimized HIS Mouse Models". The project aims to investigate the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,418,424 to Tigatx Inc., a small business located in Boston, MA, to support the late-stage development and de-risking of a novel monoclonal antibody immunotherapy called TIGA-001 for EGFR-positive solid cancers, with a focus on non-small cell lung cancer (NSCLC). The award will fund activities to progress TIGA-001 into clinical testing, including chemistry, manufacturing, and controls...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cyrus Biotechnology, Inc., a minority-owned small disadvantaged business located in Seattle, Washington. The grant supports the development of an immunoglobulin G (IgG) protease enzyme to treat immune thrombocytopenia (ITP) and other IgG-mediated autoimmune diseases. Key objectives include evaluating the immunogenicity,...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) is funding research to develop a novel cancer therapy with both immuno-activating and oncology-targeting capabilities to treat triple negative breast cancer. The $661,072 award to Northwestern University, with a subcontract to Exomira Medicine Inc., aims to advance an IND-enabling study for a first-in-class small molecule inhibitor targeting the USP22 oncogene. This multifaceted approach...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $500,928 to Pupil Bio, Inc. to develop an early detection test for Type 1 Diabetes (T1D) using next-generation sequencing (NGS) analysis of B cell-specific methylation patterns in cell-free DNA (cfDNA). The key products to be delivered through this award include: 1) Validating thousands...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...

The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...